Compare CARE & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | AURA |
|---|---|---|
| Founded | 1974 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.1M | 419.5M |
| IPO Year | 2020 | 2021 |
| Metric | CARE | AURA |
|---|---|---|
| Price | $26.17 | $7.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $25.00 | $20.00 |
| AVG Volume (30 Days) | 324.6K | ★ 653.8K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | $12.50 | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | $6.94 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $15.48 | $4.73 |
| 52 Week High | $27.24 | $9.54 |
| Indicator | CARE | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 53.46 |
| Support Level | $19.34 | $6.00 |
| Resistance Level | N/A | $9.54 |
| Average True Range (ATR) | 0.76 | 0.52 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 62.36 | 37.97 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.